- ►diabetesjournals.org P Pozzilli, U Di Mario - Diabetes Care, 2001 - Am Diabetes Assoc Type 1 diabetes is caused by the immune-mediated destruction of islet insulin-secreting
β-cells. This chronic destructive process is associated with both cellular and humoral immune
changes in the peripheral blood that can be detected months or even years before the ... Cited by 205 - Related articles - BL Direct - All 7 versions
B Isomaa, M Henricsson, P Almgren, T Tuomi, MR … - Diabetologia, 2001 - Springer Type II (non-insulin-dependent) diabetes mellitus is a heterogeneous disease involving both
impaired beta-cell function and insulin resistance [1]. A major- ity of patients with Type II diabetes
have features of ... The metabolic syndrome influences the risk of chronic Cited by 141 - Related articles - BL Direct - All 5 versions
- ►diabetesjournals.org N Hosszúfalusi, Á Vatay, K Rajczy, Z Prohászka, É … - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—There were no differences in the clinical parameters between LADA and adult-onset
type 1 diabetes. Patients with LADA had lower BMI (P < 0.0001), waist-to-hip ratio (0.0029), total
cholesterol (P = 0.001), and triglycerides (P = 0.001); higher HDL cholesterol levels (P < ... Cited by 111 - Related articles - BL Direct - All 5 versions
T Lohmann, K Kellner, HJ Verlohren, J Krug, J … - Diabetologia, 2001 - Springer Type I (insulin-dependent) diabetes mellitus is caused by specific autoimmune destruction of
pan- creatic islet cells [1]. Distinct islet cell-specific auto- antibodies (Ab), including ICA 16as
well as autoan- tibodies to insulin, glutamic acid decarboxylase (GAD) 65 or the tyrosine ... Cited by 104 - Related articles - BL Direct - All 3 versions
S Fourlanos, F Dotta, CJ Greenbaum, JP Palmer, O … - Diabetologia, 2005 - Springer Abstract 'Latent autoimmune diabetes in adults' (LADA) is the term coined to describe adults
who have a slowly progressive form of autoimmune or type 1 diabetes that can be treated initially
without insulin injections. The diagnosis of LADA is currently based on three clinical ... Cited by 89 - Related articles - BL Direct - All 3 versions
PE Beales, P Pozzilli, GS Kline - Diabetes/Metabolism Reviews - interscience.wiley.com It is also possible that your web browser is not configured or not able to display style sheets.
In this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the latest version of Microsoft or Mozilla web browser to ... Cited by 65 - Related articles - BL Direct - All 3 versions
H Borg, HJ Arnqvist, E Björk, J Bolinder, JW Eriksson, L … - Diabetologia, 2003 - Springer Aims/hypothesis. We aimed to evaluate how an aetio- logy-based classification, as recommended
in the ADA and WHO guidelines for classification of diabe- tes mellitus, matches clinical judgement
in the Diabe- tes Incidence Study in Sweden (DISS), a study cover- ing incident cases of ... Cited by 36 - Related articles - BL Direct - All 6 versions
- ►diabetesjournals.org B Zinman, SE Kahn, SM Haffner, MC O'neill, MA Heise, … - Diabetes, 2004 - Am Diabetes Assoc A number of patients with type 2 diabetes are GAD antibody positive. A Diabetes Outcome Progression
Trial (ADOPT) is a randomized, double-blind clinical trial in recently diagnosed drug-naïve patients
with type 2 diabetes that allows for the evaluation of GAD positivity in the context of ... Cited by 36 - Related articles - BL Direct - All 20 versions
H Li, B Isomaa, MR Taskinen, L Groop, T Tuomi - Diabetes Care, 2000 - Am Diabetes Assoc However, in these studies, only a family history of type 2 diabetes has been consid- ered without
taking into account the possi- ble effect of a family history of type 1 diabetes. Furthermore, it is
not known whether familial patients with type 2 dia- betes are phenotypically similar to ... Cited by 35 - Related articles - BL Direct - All 9 versions
JP Palmer, GA Fleming, CJ Greenbaum, KC Herold, LD … - Diabetes, 2004 - Am Diabetes Assoc The underlying cause of type 1 diabetes, loss of β-cell function, has become the therapeutic target
for a number of interventions in patients with type 1 diabetes. Even though insulin therapies continue
to improve, it remains difficult to achieve normal glycemic control in type 1 diabetes, ... Cited by 27 - Related articles - All 2 versions
